DISCOUNT-ZERTIFIKAT - MODERNA | Delayed Deutsche Boerse AG 05:03:04 2024-05-27 EDT | ||
| 63.3 EUR | -0.03% |
|
| Current month | -0.19% | ||
| 1 month | +0.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-27 | 63.3 | -0.03% |
| 24-05-24 | 63.32 | -0.36% |
| 24-05-23 | 63.55 | +0.16% |
| 24-05-22 | 63.45 | +0.35% |
| 24-05-21 | 63.23 | +0.08% |
Delayed Quote Deutsche Boerse AG
Last update May 27, 2024 at 05:03 am
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SW20W9 |
| ISIN | DE000SW20W93 |
| Date issued | 2023-09-01 |
| Maturity | 2024-09-20 (117 Days) |
| Parity | 1 : 1 |
| Emission price | 57.54 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 63.81 € |
|---|---|
| Lowest since issue | 50.14 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
166.6
USD
Average target price
138.5
USD
Spread / Average Target
-16.86%
- Stock Market
- Certificates
- Certificat
